Power Hour Preview: Biotech Breakouts and Allergy Innovation Lead into the Close
DENVER, Colo., Sep 05, 2025 (247marketnews.com)- As we push into the final stretch of today’s session, the late-day action is being driven by a tight pack of clinical-stage biotech disruptors, allergy care innovators, and digital real estate survivors.
Gelteq (NASDAQ:GELS) is breaking out this afternoon after announcing the commencement of preclinical trials for its novel gel-based antihistamine formulation, targeting the lucrative U.S. allergy market via the FDA 505(b)(2) pathway.
CEO Nathan Givoni noted the platform’s potential to “transform traditional pharmaceutical products,” especially where “patient compliance and dosage control are critical.” With preclinical studies led by Adgyl Lifesciences (a Eurofins partner), GELS is positioning itself as a patient-centric innovator, aiming to disrupt a $12B+ global allergy market across pediatrics, geriatrics, and animal health.
LB-100, LIXTE’s (NASDAQ:LIXT) lead compound and first-in-class PP2A inhibitor, continues to generate buzz with analysts calling it a “cancer power-up.” It’s designed to force tumors into “lethal activation” while enhancing the effectiveness of chemo and immunotherapy.
The compound is currently in trials for:
- Ovarian clear-cell carcinoma– with GlaxoSmithKline, (NYSE:GSK),
- MSS colorectal cancer– with Roche (OTCQX:RHHBY),
- Previously in soft-tissue sarcoma, with promising Phase 1 safety data.
While the MSS CRC study is on temporary enrollment pause, interest is resurging amid chatter that an expanded trial slate could be announced by year-end.
Fangdd (NASDAQ:DUO) is catching a late-session bid on renewed speculation around Beijing stimulus measures. The company, a digital real estate marketplace, has been restructuring to reduce reliance on high-risk developers.
After weeks of heavy selling pressure, Nuvation Bio (NYSE:NUVB) is showing signs of stabilization as traders rotate into beaten-down clinical-stage names. The company’s focus on differentiated small molecules targeting tumor drivers remains compelling, but investor fatigue around long timelines has capped gains.
American Bitcoin (NASDAQ:ABCD), which blends blockchain infrastructure with data center services, continues to shadow crypto sentiment. Bitcoin’s latest rebound has sparked renewed retail interest.
Equillium (NASDAQ:EQ) is quietly climbing ahead of expected Q4 updates on its first-in-class itolizumab pipeline, targeting immune and inflammatory diseases. Though volume is light, institutional whispers suggest a major partnership or licensing event may be in the works.
Gossamer Bio (NASDAQ:GOSS) is gaining steam after weeks of consolidation, fueled by hopes for new data on its seralutinib program for pulmonary arterial hypertension (PAH). The company previously posted mixed Phase 2 data, but bulls are betting on a path forward in combo therapy trials.
Kindly MD (NASDAQ:KMD), a recent uplist from OTC to NASDAQ, is riding waves in its first full week of trading. The company focuses on integrative and medical cannabis-based solutions for pain, addiction, and behavioral health. With expanding clinics in Utah and new insurance partnerships, KMD is emerging as a mission-driven wellness platform.
Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com